Phase II Trial Evaluating BL-B01D1 and SI-B003 Alone or Combined for Treating Extensive-Stage Small Cell Lung Cancer in Adults

What this Trial Is About

Researchers are evaluating the effectiveness and safety of three treatmentsBL-B01D1 alone, SI-B003 alone, and their combinationin patients with extensive-stage small cell lung cancer. This is a phase II clinical trial aimed at understanding how these treatments work individually and together in this patient group. The study is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. Participants will receive one of the three treatments during a first cycle lasting three weeks, administered by intravenous infusion. Those who benefit from the initial treatment may continue receiving additional cycles. Treatment will stop if the disease worsens, toxicity becomes intolerable, or for other reasons determined by the study. Throughout the study, researchers will measure how many patients respond to treatment and the recommended dose for phase II, over about 24 months. They will also monitor disease progression, control rates, response duration, and any adverse events. Patients will undergo assessments such as tumor tissue sampling and regular health evaluations to track outcomes and safety during this period.

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer